More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$9.74B
EPS
3.31
P/E ratio
22.4
Price to sales
0.64
Dividend yield
--
Beta
0.806162
Previous close
$84.53
Today's open
$84.53
Day's range
$84.43 - $86.01
52 week range
$61.95 - $89.34
show more
CEO
Stanley M. Bergman
Employees
25000
Headquarters
Melville, NY
Exchange
Nasdaq Global Select
Shares outstanding
113916757
Issue type
Common Stock
Healthcare
Medical Distributors
Are Investors Undervaluing Henry Schein (HSIC) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research • Jul 23, 2026

Henry Schein to Webcast Second Quarter 2026 Conference Call on Tuesday, August 4, 2026, at 8:00 a.m. ET
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2026 financial results before the stock market opens on Tuesday, August 4, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Fred Lowery, Chief Executive Officer and.
Business Wire • Jul 21, 2026

Will Henry Schein (HSIC) Beat Estimates Again in Its Next Earnings Report?
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks Investment Research • Jul 20, 2026

Zacks Industry Outlook McKesson, Cardinal, West Pharmaceutical, Align and Henry
McKesson, Cardinal, West Pharmaceutical, Align and Henry have been highlighted in this Industry Outlook article.
Zacks Investment Research • Jul 14, 2026

5 Medical Supply Stocks to Buy Amid Strong Industry Tailwinds
Here, we highlight five dental supplies stocks, MCK, CAH, WST, ALGN and HSIC, which are well positioned to generate wealth for investors amid improving industry prospect.
Zacks Investment Research • Jul 13, 2026

Is Henry Schein (HSIC) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research • Jul 7, 2026

GoTu and Henry Schein Announce Strategic Partnership to Strengthen Dental Workforce Support Nationwide
MIAMI, June 30, 2026 /PRNewswire/ -- GoTu Technology, the nation's leading dental talent marketplace, and Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced a new strategic partnership designed to help dental practices address ongoing staffing challenges and maintain continuity of patient care. Through this collaboration between GoTu and Henry Schein Dental Recruitment Services (a division of Henry Schein Financial Enterprises, LLC, a wholly-owned subsidiary of Henry Schein), dental practices will gain expanded access to GoTu's technology-enabled platform, which connects offices with qualified dental hygienists, dental assistants, and associate dentists for both temporary and permanent staffing needs.
PRNewsWire • Jun 30, 2026

Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research • Jun 23, 2026

Henry Schein: Smile Because The Upside Isn't Over
Henry Schein remains a dominant global provider in dental and medical practitioner supplies, with strong market shares and ongoing revenue growth. HSIC's Q1 2026 revenue grew 6.3% year-over-year, driven by robust global dental merchandise and equipment demand, particularly in aging and expanding populations. Profitability metrics are mixed, but adjusted net income and EBITDA are rising; management guides for 3–5% revenue growth and mid-single-digit EBITDA growth in 2026.
Seeking Alpha • Jun 22, 2026

This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Benzinga • Jun 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Henry Schein Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.